AstraZeneca tumor drug: AstraZeneca, Daiichi Drug gets broad tumor approval in US
Enhertu, a collaboration between AstraZeneca and Daiichi Sankyo, gains FDA approval for treating HER2-positive solid tumors spread throughout the body, marking a breakthrough in cancer treatment. Its the first antibody drug conjugate with such wide clearance, offering new hope for patients with limited treatment options. AstraZeneca anticipates further growth opportunities.
Source: indiatimes.com